Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.

Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, Akova M, Yu Y.

Clin Microbiol Infect. 2019 Sep 5. pii: S1198-743X(19)30483-5. doi: 10.1016/j.cmi.2019.08.020. [Epub ahead of print]

PMID:
31494252
2.

Dual Role of gnaA in Antibiotic Resistance and Virulence in Acinetobacter baumannii.

Xu Q, Chen T, Yan B, Zhang L, Pi B, Yang Y, Zhang L, Zhou Z, Ji S, Leptihn S, Akova M, Yu Y, Hua X.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00694-19. doi: 10.1128/AAC.00694-19. Print 2019 Oct.

PMID:
31358579
3.

Ultrastructural evaluation of urine alkalinization versus hydration on colistin-induced nephrotoxicity.

Korucu B, Unal I, Pekcan M, Inkaya AC, Yeter H, Cetinkaya MA, Kaymaz FF, Unal S, Akova M, Erdem Y.

Hum Exp Toxicol. 2019 Dec;38(12):1366-1377. doi: 10.1177/0960327119862339. Epub 2019 Jul 7.

PMID:
31280613
4.

Infections in the Elderly Critically-Ill Patients.

Esme M, Topeli A, Yavuz BB, Akova M.

Front Med (Lausanne). 2019 Jun 6;6:118. doi: 10.3389/fmed.2019.00118. eCollection 2019. Review.

5.

Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study.

Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, García E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, Maestro de la Calle G, Manzur A, Marin JI, Márquez-Gómez I, Martín-Dávila P, Mikulska M, Montejo JM, Montero M, Morales HMP, Morales I, Novo A, Oltolini C, Peghin M, Del Pozo JL, Puerta-Alcalde P, Ruiz-Camps I, Sipahi OR, Tilley R, Yáñez L, Gomes MZR, Carratalà J; IRONIC study group.

BMJ Open. 2019 May 24;9(5):e025744. doi: 10.1136/bmjopen-2018-025744.

6.

Immigrants as donors and transplant recipients: specific considerations.

Poulakou G, Len O, Akova M.

Intensive Care Med. 2019 Mar;45(3):401-403. doi: 10.1007/s00134-019-05534-z. Epub 2019 Jan 30. No abstract available.

PMID:
30701293
7.

Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project.

Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, Grecchi C, Rebuffi C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, Azoulay E, Blot SI, Cornely OA, Lass-Flörl C, Koehler P, Cuenca-Estrella M, de Lange DW, De Rosa FG, De Waele JJ, Dimopoulos G, Garnacho-Montero J, Hoenigl M, Kanj SS, Maertens J, Martin-Loeches I, Muñoz P, Kullberg BJ, Agvald-Ohman C, Poulakou G, Rello J, Sanguinetti M, Taccone FS, Timsit JF, Torres A, Vazquez JA, Calandra T; from the Study Group for Infections in Critically Ill Patients (ESGCIP) and the Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); European Society of Intensive Care Medicine (ESICM); European Confederation of Medical Mycology (ECMM); Mycoses Study Group Education and Research Consortium (MSGERC).

Mycoses. 2019 Apr;62(4):310-319. doi: 10.1111/myc.12869. Epub 2019 Jan 22.

PMID:
30426598
8.

Correction to: Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Bassetti M, Akova M, Tumbarello M.

Intensive Care Med. 2018 Dec;44(12):2324. doi: 10.1007/s00134-018-5411-6.

PMID:
30413839
9.

Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Bassetti M, Akova M, Tumbarello M.

Intensive Care Med. 2018 Nov;44(11):1982-1984. doi: 10.1007/s00134-018-5390-7. Epub 2018 Sep 28. No abstract available. Erratum in: Intensive Care Med. 2018 Nov 9;:.

PMID:
30267137
10.

ESCMID white paper: a guide on ESCMID guidance documents.

Scudeller L, Rodríguez-Baño J, Zinkernagel A, Tacconelli E, Akova M, Friedrich AW, Sanguinetti M, Paul M, Poljak M.

Clin Microbiol Infect. 2019 Feb;25(2):155-162. doi: 10.1016/j.cmi.2018.08.005. Epub 2018 Aug 24.

PMID:
30145398
11.

Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodríguez-Baño J, Venditti M; REIPI/ESGBIS/INCREMENT investigators.

Int J Antimicrob Agents. 2018 Nov;52(5):577-585. doi: 10.1016/j.ijantimicag.2018.06.018. Epub 2018 Jun 30.

PMID:
29969692
12.

Neuroinvasive Listeriosis: Could Petechial Hemorrhages be a Diagnostic Clue?

Diker S, Okar S, Mehdikhanova L, Arsava EM, Kurne A, Çevik IÜ, Akyön Y, Alp Ş, İnkaya Ç, Akova M, Mut M, Göçmen R, Oğuz KK, Topçuoğlu MA.

Neurologist. 2018 May;23(3):86-91. doi: 10.1097/NRL.0000000000000170.

PMID:
29722741
13.

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):660-667. doi: 10.1017/ice.2018.63. Epub 2018 Apr 5.

PMID:
29618394
14.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

15.

Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.

Averbuch D, Orasch C, Mikulska M, Livermore DM, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, Calandra T, Cordonnier C; ECIL4 antibacterial group, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN.

Clin Microbiol Infect. 2018 Jun;24(6):662-663. doi: 10.1016/j.cmi.2018.01.012. Epub 2018 Feb 2. No abstract available.

16.

Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.

De Waele JJ, Akova M, Antonelli M, Canton R, Carlet J, De Backer D, Dimopoulos G, Garnacho-Montero J, Kesecioglu J, Lipman J, Mer M, Paiva JA, Poljak M, Roberts JA, Rodriguez Bano J, Timsit JF, Zahar JR, Bassetti M.

Intensive Care Med. 2018 Feb;44(2):189-196. doi: 10.1007/s00134-017-5036-1. Epub 2017 Dec 29.

PMID:
29288367
17.

Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: A Clinical and Microbiological Study.

Tan Y, Zhou K, Tang X, Kudinha T, Wang L, Guo Z, Akova M, Zhuo C.

Sci Rep. 2017 Nov 10;7(1):15279. doi: 10.1038/s41598-017-13148-y.

18.

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.

Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C; European Conference on Infections in Leukemia (ECIL).

J Infect. 2018 Jan;76(1):20-37. doi: 10.1016/j.jinf.2017.10.009. Epub 2017 Oct 25.

PMID:
29079323
19.

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group.

Clin Infect Dis. 2017 Oct 30;65(10):1615-1623. doi: 10.1093/cid/cix606.

20.

Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.

Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J; ESGBIS/REIPI/INCREMENT Group.

Int J Antimicrob Agents. 2017 Nov;50(5):664-672. doi: 10.1016/j.ijantimicag.2017.08.005. Epub 2017 Aug 3.

PMID:
28782704
21.

Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.

Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Tebe C, Carratalà J; BICAR Study Group.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00164-17. doi: 10.1128/AAC.00164-17. Print 2017 Aug.

22.

ESCMID-an international Europe-based society committed to fostering cross-border collaboration and education to improve patient care.

Poljak M, Akova M, Friedrich AW, Rodríguez-Baño J, Sanguinetti M, Tacconelli E, Zinkernagel A.

Clin Microbiol Infect. 2018 Jan;24(1):1-2. doi: 10.1016/j.cmi.2017.05.024. Epub 2017 Jun 2. No abstract available.

23.

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.

Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.

PMID:
28442293
24.

Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study.

Quan J, Li X, Chen Y, Jiang Y, Zhou Z, Zhang H, Sun L, Ruan Z, Feng Y, Akova M, Yu Y.

Lancet Infect Dis. 2017 Apr;17(4):400-410. doi: 10.1016/S1473-3099(16)30528-X. Epub 2017 Jan 28.

PMID:
28139430
25.

[Evaluation of PNA-FISH method for direct identification of Candida species in blood culture samples and its potential impact on guidance of antifungal therapy].

Doğan Ö, İnkaya AÇ, Gülmez D, Uzun Ö, Akova M, Arıkan Akdağlı S.

Mikrobiyol Bul. 2016 Oct;50(4):580-589. Turkish.

26.

Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).

Gudiol C, Royo-Cebrecos C, Tebe C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Carratalà J; BICAR study group.

BMJ Open. 2017 Jan 23;7(1):e013268. doi: 10.1136/bmjopen-2016-013268.

27.

Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.

Alp S, Akova M.

Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017002. doi: 10.4084/MJHID.2017.002. eCollection 2017. Review.

28.

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.

J Antimicrob Chemother. 2017 Mar 1;72(3):906-913. doi: 10.1093/jac/dkw513.

29.

An overview on severe infections in Europe.

Dimopoulos G, Akova M.

Intensive Care Med. 2017 May;43(5):686-689. doi: 10.1007/s00134-016-4650-7. Epub 2016 Dec 19. Review. No abstract available.

PMID:
27995284
30.

Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?

Metan G, Akova M.

Curr Opin Infect Dis. 2016 Dec;29(6):555-560. Review.

PMID:
27584588
31.

Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination.

Blasi F, Akova M, Bonanni P, Dartois N, Sauty E, Webber C, Torres A.

Eur J Intern Med. 2017 Jan;37:13-18. doi: 10.1016/j.ejim.2016.09.024. Epub 2016 Oct 15. Review.

PMID:
27756499
32.

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group.

Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024. Erratum in: Mayo Clin Proc. 2016 Dec;91(12 ):1843.

PMID:
27712635
33.

High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China.

Quan J, Zhao D, Liu L, Chen Y, Zhou J, Jiang Y, Du X, Zhou Z, Akova M, Yu Y.

J Antimicrob Chemother. 2017 Jan;72(1):273-280. Epub 2016 Sep 13.

PMID:
27624571
34.

Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013.

Zarakolu P, Eser OK, Aladag E, Al-Zahrani IA, Day KM, Atmaca O, Boral B, Cakir B, Perry JD, Akova M.

Diagn Microbiol Infect Dis. 2016 Aug;85(4):466-70. doi: 10.1016/j.diagmicrobio.2016.05.012. Epub 2016 May 21.

PMID:
27306118
35.

Corrigendum to "The global threat of antimicrobial resistance: science for intervention" [New Microbes New Infect 6 (2015): 22-29].

Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heuer OE, Kahlmeter G, Kruse H, Laxminarayan R, Liébana E, López-Cerero L, MacGowan A, Martins M, Rodríguez-Baño J, Rolain JM, Segovia C, Sigauque B, Tacconelli E, Wellington E, Vila J.

New Microbes New Infect. 2015 Sep 10;8:175. doi: 10.1016/j.nmni.2015.09.004. eCollection 2015 Nov.

36.

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4159-69. doi: 10.1128/AAC.00365-16. Print 2016 Jul.

37.

Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality.

Çalık Başaran N, Karaağaoğlu E, Hasçelik G, Durusu Tanrıöver M, Akova M.

Turk J Haematol. 2016 Dec 1;33(4):311-319. doi: 10.4274/tjh.2015.0216. Epub 2016 Apr 18.

38.

Epidemiology of antimicrobial resistance in bloodstream infections.

Akova M.

Virulence. 2016 Apr 2;7(3):252-66. doi: 10.1080/21505594.2016.1159366. Review.

39.

Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origüen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.

J Antimicrob Chemother. 2016 Jun;71(6):1672-80. doi: 10.1093/jac/dkv502. Epub 2016 Feb 22.

40.

Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Garnacho-Montero J, Dimopoulos G, Poulakou G, Akova M, Cisneros JM, De Waele J, Petrosillo N, Seifert H, Timsit JF, Vila J, Zahar JR, Bassetti M; European Society of Intensive Care Medicine.

Intensive Care Med. 2015 Dec;41(12):2057-75. doi: 10.1007/s00134-015-4079-4. Epub 2015 Oct 5.

PMID:
26438224
41.

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Dulhunty J, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Roberts JA; DALI Study Group.

J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3.

PMID:
26433783
42.

Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).

Boğa C, Bolaman Z, Çağırgan S, Karadoğan İ, Özcan MA, Özkalemkaş F, Saba R, Sönmez M, Şenol E, Akan H, Akova M.

Turk J Haematol. 2015 Jun;32(2):100-17. doi: 10.4274/tjh.2014.0277. Review.

43.
44.

Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010.

Alp S, Arikan-Akdagli S, Gulmez D, Ascioglu S, Uzun O, Akova M.

Mycoses. 2015 Aug;58(8):498-505. doi: 10.1111/myc.12349. Epub 2015 Jul 7.

PMID:
26155849
45.

The global threat of antimicrobial resistance: science for intervention.

Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heuer OE, Kahlmeter G, Kruse H, Laxminarayan R, Liébana E, López-Cerero L, MacGowan A, Martins M, Rodríguez-Baño J, Rolain JM, Segovia C, Sigauque B, Tacconelli E, Wellington E, Vila J.

New Microbes New Infect. 2015 Apr 16;6:22-9. doi: 10.1016/j.nmni.2015.02.007. eCollection 2015 Jul. Review. Erratum in: New Microbes New Infect. 2015 Nov;8:175.

46.

Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.

Kara Ö, Zarakolu P, Aşçioğlu S, Etgül S, Uz B, Büyükaşik Y, Akova M.

Infect Dis (Lond). 2015;47(10):686-93. doi: 10.3109/23744235.2015.1051105. Epub 2015 May 29.

PMID:
26024284
47.

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.

Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Dimopoulos G; DALI Study authors.

Crit Care. 2015 Feb 4;19:33. doi: 10.1186/s13054-015-0758-3.

48.

Erratum to: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.

De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Udy AA, Starr T, Wallis SC, Roberts JA.

Intensive Care Med. 2015 May;41(5):969. doi: 10.1007/s00134-015-3772-7. No abstract available.

PMID:
25820545
49.

Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical.

Orasch C, Averbuch D, Mikulska M, Cordonnier C, Livermore DM, Gyssens IC, Klyasova G, Engelhard D, Kern W, Viscoli C, Akova M, Marchetti O; 4th European Conference on Infections in Leukemia (ECIL-4); joint venture of Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (IDWP-EBMT); Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (IDG-EORTC); International Immunocompromised Host Society (ICHS); European Leukemia Net (ELN) and European Study Group on Infections in Immunocompromised Hosts of the European Society for Clinical Microbiology and Infectious Diseases (ESGICH-ESCMID).

Clin Microbiol Infect. 2015 Mar;21(3):e25-7. doi: 10.1016/j.cmi.2014.10.014. Epub 2014 Dec 18. No abstract available.

50.

Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey.

Zarakolu P, Day KM, Sidjabat HE, Kamolvit W, Lanyon CV, Cummings SP, Paterson DL, Akova M, Perry JD.

Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):519-25. doi: 10.1007/s10096-014-2255-z. Epub 2014 Oct 12.

PMID:
25308827

Supplemental Content

Support Center